Zentexia ApS

Zentexia is a Danish R&D company focused on developing novel small molecules aimed at reversing aging at the cellular level. The company utilizes a proprietary interdisciplinary approach that integrates artificial intelligence (AI) and advanced systems biology to optimize drug discovery, minimize development risk, and enhance the probability of success in therapeutic development. Zentexia operates as an innovation-focused entity that generates intellectual property and therapeutic concepts for the life science industry. Its business model involves maturing assets in collaboration with investors or partners, often through dedicated sister project companies, targeting both pharmaceutical and regulatory categories such as medical devices.